Abstract: A method and device for controlling an air conditioner, and a computer readable storage medium. The method for controlling an air conditioner includes: upon detecting a power-on or power-off command corresponding to an internal unit of a central air conditioner, acquiring a current predicted load of the central air conditioner; determining whether the predicted load meets an external unit change condition; and if so, adjusting an operating state of an external unit of the central air conditioner on the basis of the predicted load.

Abstract: A method for delivering a medication for treatment of a pulmonary disease depending on location(s) of infection lesion(s) within a respiratory tract of a patient is disclosed. The method includes administering metered doses of the medication to the patient having the pulmonary disease by a metered dose inhaler (MDI) actuator having a function of controlling drug particle delivery characteristics. The medication is effective for treating the pulmonary disease. A therapeutically effective amount of medication for treating the pulmonary disease is administered by various metered doses of the medication. The medication includes an active pharmaceutical ingredient (API) associated with treatment of a pulmonary disease. The medication includes a propellant, a co-solvent, and a surfactant. The API is dissolved in the propellant at a pre-determined ratio, with or without a co-solvent. The medication is administered via metered-dose inhalation.

Abstract: The present disclosure introduces pharmaceutical formulations having epinephrine as the active pharmaceutical ingredient (API), and a bile acid, or salt thereof (e.g., sodium taurocholate (STC)) as an absorption enhancer, for intranasal (IN) delivery. The bile acid, or the salt thereof, enhances absorption of epinephrine by IN delivery. Also disclosed are methods of administering epinephrine to a patient by IN delivery using the disclosed epinephrine formulations for various treatments or indications.

Abstract: A method for controlling an ice storage air-conditioning system includes: adjusting parameters of the ice storage air-conditioning system in a current cooling mode or when switching a cooling mode based on an outlet temperature of a plate heat exchanger of the ice storage air-conditioning system; and controlling the ice storage air-conditioning system to perform a cooling operation based on the parameters of the ice storage air-conditioning system.

Abstract: An air conditioner water system, a control method therefor, and a control device thereof, the method includes acquiring the pressure difference and temperature difference between a water intake pipe and a water discharge pipe of an air conditioner water system, the water intake pipe being connected to an inlet of a host module of the air conditioner water system, and the water discharge pipe being connected to an outlet of the host module; detecting and confirming that the pressure difference is less than or equal to a preset pressure difference, and controlling the operating frequency of a water pump of the air conditioner water system according to the pressure difference; and detecting and confirming that the pressure difference is greater than the preset pressure difference, and controlling the operating frequency of the water pump of the air conditioner water system according to the temperature difference.

Abstract: The present disclosure generally pertains to a medical device and more particularly, a metered-dose inhaler (“MDI”) actuator capable of a targeted delivery of fine API particles having particle diameters of about 1.1 ?m or less to a portion of a patient's lungs where alveoli are located.

Abstract: The present disclosure introduces safe and effective pharmaceutical formulations for intranasal delivery. Specifically, the present disclosure introduces the safe clinical use of bile acids or salts thereof as an enhancer to exhibit improved bioavailability and tissue tolerance. In several embodiments, pharmaceutical formulations including bile acids or salts thereof are provided. In several embodiments, the formulations are suitable and/or configured for the intranasal (IN) delivery, methods of manufacturing such formulations, and methods of treating patients using such formulations. The pharmaceutical formulations comprising bile acids, salts of bile acids, and/or combinations thereof. In several embodiments, bile acids, salts of bile acids, and/or combinations thereof are configured for use as absorption enhancers.

Abstract: The present disclosure introduces intranasal (IN) pharmaceutical formulations having naloxone or an opioid antagonist as the active agent, and an absorption enhancer, such as a bile acid, or a salt thereof, for IN delivery. The bile acid, or salt thereof, enhances absorption of naloxone or an opioid antagonist into the bloodstream of a human subject.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: The present disclosure provides NMR relaxation methods for characterizing iron carbohydrate drug products. The methods measure 13C and 1H nuclei relaxation parameters such as T1 and PWHH include performing 2D T1 NMR, 1D 13C NMR and 1H NMR to characterize certain physiochemical properties of iron sucrose drug products, for purposes of assessing bioequivalence between a tested iron sucrose product and a comparator product. The disclosure further provides a novel Fe(III)/Fe(II) reduction method using a new reducing agent Na2S2O5 and an 1H NMR method to monitor the Fe(III)/Fe(II) reduction process.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido AsnA21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less. Also disclosed are API compositions of highly purified RHI having a purity of 99.0% (w/w) or greater, a Total Impurity of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.

Abstract: A method and device for controlling an air conditioner, and a computer readable storage medium. The method for controlling an air conditioner includes: upon detecting a power-on or power-off command corresponding to an internal unit of a central air conditioner, acquiring a current predicted load of the central air conditioner; determining whether the predicted load meets an external unit change condition; and if so, adjusting an operating state of an external unit of the central air conditioner on the basis of the predicted load.

Abstract: An air conditioner water system, a control method therefor, and a control device thereof, the method includes acquiring the pressure difference and temperature difference between a water intake pipe and a water discharge pipe of an air conditioner water system, the water intake pipe being connected to an inlet of a host module of the air conditioner water system, and the water discharge pipe being connected to an outlet of the host module; detecting and confirming that the pressure difference is less than or equal to a preset pressure difference, and controlling the operating frequency of a water pump of the air conditioner water system according to the pressure difference; and detecting and confirming that the pressure difference is greater than the preset pressure difference, and controlling the operating frequency of the water pump of the air conditioner water system according to the temperature difference.

Abstract: Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido AsnA21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less. Also disclosed are API compositions of highly purified RHI having a purity of 99.0% (w/w) or greater, a Total Impurity of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.

Abstract: A composite material preparation system comprises a sealed reaction kettle for containing reactants and base materials; temperature and pressure detecting units for detecting the temperature and pressure inside the reaction kettle; and a heating unit for hydrothermally induced heating, based on the detected temperature and pressure values. The heating unit comprises an induction coil, an induction heating device, and a control mechanism for controlling the generation of an induction frequency of the induction heating device. The reaction kettle is located in the induction coil, both ends of the induction coil are mounted on an outer wall of the induction heating device, and the induction coil and the induction heating device have circulating water introduced inside. The device can prepare a composite material having good interface bonding, by utilizing induced heating under the premise of controllable temperature and pressure, and by utilizing the characteristic that the reactants themselves are heated.

Abstract: Provided is a method for the preparation of a porous hollow shell WO3/WS2 nanomaterial, comprising: (1) adding a hexavalent tungsten salt to a sol A comprising mesocarbon microbeads, and stirring to obtain a sol B; (2) drying and grinding the sol B, and then heating a resulting powder at 200-500° C. for 0.5-2 hours to obtain a porous hollow shell WO3 nanocrystalline material; (3) placing the porous hollow shell WO3 nanocrystalline material obtained by Step 2 and a sulfur powder separately in a vacuum furnace, controlling such that a degree of vacuum is ?0.01 to ?0.1 MPa and a temperature is 200-500° C., and reacting for 0.5-3 hours to obtain a WO3/WS2 porous hollow shell nanocrystalline material. Also provided is a porous hollow shell WO3/WS2 nanocrystalline material obtained by the method.

Abstract: A composite material preparation system comprises a sealed reaction kettle for containing reactants and base materials; temperature and pressure detecting units for detecting the temperature and pressure inside the reaction kettle; and a heating unit for hydrothermally induced heating, based on the detected temperature and pressure values. The heating unit comprises an induction coil, an induction heating device, and a control mechanism for controlling the generation of an induction frequency of the induction heating device. The reaction kettle is located in the induction coil, both ends of the induction coil are mounted on an outer wall of the induction heating device, and the induction coil and the induction heating device have circulating water introduced inside. The device can prepare a composite material having good interface bonding, by utilizing induced heating under the premise of controllable temperature and pressure, and by utilizing the characteristic that the reactants themselves are heated.

Abstract: Provided is a method for the preparation of a porous hollow shell WO3/WS2 nanomaterial, comprising: (1) adding a hexavalent tungsten salt to a sol A comprising mesocarbon microbeads, and stirring to obtain a sol B; (2) drying and grinding the sol B, and then heating a resulting powder at 200-500° C. for 0.5-2 hours to obtain a porous hollow shell WO3 nanocrystalline material; (3) placing the porous hollow shell WO3 nanocrystalline material obtained by Step 2 and a sulfur powder separately in a vacuum furnace, controlling such that a degree of vacuum is ?0.01 to ?0.1 MPa and a temperature is 200-500° C., and reacting for 0.5-3 hours to obtain a WO3/WS2 porous hollow shell nanocrystalline material. Also provided is a porous hollow shell WO3/WS2 nanocrystalline material obtained by the method.